Kangzhe Pharmaceutical (00867.HK): Innovative drug high selective TYK2 inhibitor CMS-D001 obtained approval for clinical trial notification for the indications of ulcerative colitis and Crohn's disease.

Intelligence Finance APP news, Kangzhi Pharmaceutical (00867.HK) announced that on May 22, 2026, the innovative drug CMS-D001 tablet (CMS-D001 or product) received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA) of China, and received the Drug Clinical Trial Approval Notice on May 25. NMPA has approved the Group to conduct clinical trials to evaluate the safety and effectiveness of CMS-D001 in the treatment of ulcerative colitis and Crohn's disease indications.